Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Cash from Financing Activities (2024 - 2025)

BioAge Labs (BIOA) has disclosed Cash from Financing Activities for 2 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 35.7% to $16.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, down 96.99% year-over-year, with the annual reading at $11.5 million for FY2025, 96.99% down from the prior year.
  • Cash from Financing Activities hit $16.0 million in Q4 2025 for BioAge Labs, up from -$1.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q3 2024 to a low of -$2.4 million in Q2 2024.